Clinical Trial Update: Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update evaluating the safety and efficacy of REP 9AC (REP 2055) in patients with chronic hepatitis B or hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• REP 9AC (REP 2055) (REP 9AC)

Snippet

Sponsor: Replicor Inc. | Conditions: Hepatitis B, Chronic | Phase 1, Phase 2 | Status: COMPLETED